期刊文献+

Cdc42表达载体构建及协同药物对细胞迁移的影响

Construction of Cdc42 Expression Vector and the Effect of It Coordinating with the Peptidomimetics on Cell Migration
下载PDF
导出
摘要 为了研究Cdc42协同拟肽化合物对A549细胞迁移的影响,构建携带红、绿荧光报告基因的Cdc42真核表达载体,转染293T细胞,观察基因表达情况;测定实验用化合物(PMC4)对A549细胞的毒性;进一步将Cdc42转染高迁移率的A549细胞,然后用拟肽化合物刺激,通过细胞划痕实验,初步检测Cdc42协同拟肽化合物对A549细胞迁移的影响。结果表明:本实验成功构建了Cdc42异构体基因的真核表达载体pGFP-cdc42-2、pGFP-cdc42-3、pRed-cdc42-2、pRed-cdc42-3,转染293T细胞效率约为90%;10 μmol/L的拟肽化合物对A549细胞毒性微弱,拟肽药物分子末端对位上的取代基为氟时,其对细胞迁移具有促进作用,过表达Cdc42时,Cdc42协同药物使细胞迁移进一步增加,具体机制有待进一步研究。 In order to study the effect of Cdc42 coordinating with the peptidomimetics on the migration of A549 cells, the Cdc42 eukaryotic expression vectors harboring fluorescent reporter genes were constructed and transfected into 293T cells. The expression of Cdc42 was observed by fluorescence microscopy. The cytotoxicity of the compound (PMC4) on A549 cells was tested. The Cdc42 genes were further ex- pressed in the high mobility cells A549 and the compound was added. The cooperation effect of Cdc42 with the compound on the cell migration was investigated by cell wound scratch assay. The results showed that the eukaryotic expression vectors of Cdc42 isoform genes were successfully constructed named pGFP-cdc42-2, pGFP-cdc42-3, pRed-cdc42-2, pRed-cdc42-3 respectively. These recombinants plasmids were transfected into 293T cells and the transfection ef-ficiency was about 90%. 10 μmol/L peptidomimetic compounds showed weak toxicity to A549 cells. When the substituent group at the terminal para-position of the peptidomimetic drug molecule is F (fluorin), it can increase the migration of A549 cells. While the Cdc42 gene was over-expressed in A549 cells and the cell migration rate was enhanced furtherly. More studies and results need to be carried out to reveal the detail mechanism.
出处 《生物医学》 CAS 2021年第3期176-185,共10页 Hans Journal of Biomedicine
  • 相关文献

参考文献2

二级参考文献24

  • 1高砚春,吴诚义.乳腺癌耐药蛋白的研究现状[J].中国普通外科杂志,2005,14(9):702-704. 被引量:1
  • 2BAUVOIS B, DAUZONNE D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic pmspects[J ]. Med Res Rev, 2006, 26(1) :88 - 130
  • 3MIZUTANI S, SHIBATA K, KIKKAWA F, et al. Essential role of placental leueine aminopeptidase in gynecologic malignancy [ J ]. Expert Opin Ther Targets, 2007, 11(4) :453 - 461
  • 4SAIKI I, FUJII H, YONEDA J, et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation(p 137 - 143) [J]. Int J Cancer, 1993, 54(1) : 137 - 143.
  • 5MENRAD A, SPEICHER D, WACKER J, et al. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells[J]. Cancer Res, 1993, 53(6):1450 - 1455.
  • 6CHEN H, ROQUES B P, FOURNIE-ZALUSKI M C. Design of the first highly potent and selective aminopeptidase N(EC 3.4.11.2) inhibitor[J]. Bioorg Med Chem Lett, 1999, 9(11) :1511 - 1516
  • 7LEVY M, PALMER A H. The benzoylation and resolution alanine[J]. J Biol Chem, 1942, 146 (2) : 493 - 495.
  • 8SONG K S, ISHIKAWA Y, KOBAYASHI S, et al. N-acylamino acids from Ephedra distachya cultures [J]. Phytochemistry, 1992, 31(3) :823 - 826.
  • 9SCHRODER J, HENKE A, WENZEL H. Structure- based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1, 3, 4-thiadiazine scaffold[J]. J Mied Chem, 2001, 44 (20) : 3231 - 3243.
  • 10LEJCZAK B, KAFARSHI P, ZYGMUNT J. Inhibition of aminopeptidases by aminophosphonates [J ]. Biochemistry, 1989, 28(8) :3549 - 3555.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部